ArticleFrontiers in endocrinology2026
Steroid hormones in early pregnancy and adverse birth outcomes: a Chinese birth cohort.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adverse birth outcomes (ABOs) are major public health concerns. While maternal steroid hormones are essential for fetal development, their individual and combined effects on ABO remain unclear. Methods: This prospective cohort study included 364 pregnant women (30.7 ± 4.0 years) in Guangzhou, China. Nineteen steroid hormones were measured by LC-MS/MS. Regression and Qgcomp models were used to assess individual and combined associations with ABO, including low birth weight, macrosomia, small for gestational age (SGA), large for gestational age, and preterm birth. Results: Pregnant women with ABO had higher levels of androstenedione (A4) and testosterone (T) and lower levels of 11-deoxycortisol (11-DOF) and estriol (E3). In linear regression models, each 1-SD increase in cortisol (F) was associated with increases of 0.18 cm (95% CI: 0.02, 0.34) in birth length and 0.24 cm (95% CI: 0.04, 0.44) in head circumference, whereas estrone (E1) was inversely associated with gestational age (-0.20 weeks, 95% CI: -0.36, -0.05). In logistic regression analyses, each 1-SD increase in A4 (OR = 1.36, 95% CI: 1.07, 1.72), T (OR = 1.37, 95% CI: 1.08, 1.73), and dihydrotestosterone (DHT) (OR = 1.32, 95% CI: 1.03, 1.69) was associated with higher odds of ABO, whereas 11-DOF was inversely associated with ABO (OR = 0.70, 95% CI: 0.50, 0.98). For SGA, each 1-SD increase in A4 (OR = 1.40, 95% CI: 1.01, 1.94) and T (OR = 1.47, 95% CI: 1.08, 1.99) was associated with increased risk, whereas F (OR = 0.84, 95% CI: 0.72, 0.97) and 11-DOF (OR = 0.58, 95% CI: 0.35, 0.95) were inversely associated. In Qgcomp analyses, the androgen mixture was associated with ABO (OR = 1.40, 95% CI: 1.00, 1.97) and SGA (OR = 1.77, 95% CI: 1.04, 3.01), with A4 and T contributing the largest weights. Consistent directional patterns were observed for androgen-related hormones across outcomes and analytical approaches. Conclusions: Maternal hormonal milieu in early pregnancy may be associated with fetal growth and ABO risk, with consistent patterns for androgen-related hormones. These findings are exploratory and require validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.